
Fig. 1

-2007

1200 - 1000 - 800 - 600 - 400 - 200 - 200 - 200 - 200 - 1200 - 200

Signal



4000 -

0009

10000

Signal

16000 -




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9






Fig. 10








Time (minutes)


Fig. 11


Fig. 12

















Fig.13




Fig. 14




Fig. 15A




Fig. 15B






Fig. 16








Fig. 17




Fig. 18





Fig. 19

Fig. 20


Significant decrease of mtDNA in PBMC



Weeks after start of therapy


Fig. 21





days since start treatment

Fig. 22







Fig. 23






Fig. 24

Percentage of patients changing ART because of adverse effects Adverse effects of antiretroviral therapy

(results from the ATHENA-study in the Netherlands)





Fig. 25



# DNA-NASBA amplification

Fig. 26

